C

Cytosorbents Corp
D

CTSO

0.91900
USD
0.02
(2.74%)
Market Closed
Volume
2,382
EPS
-0
Div Yield
-
P/E
-3
Market Cap
50,250,524
OverviewSignalsIdeasNews
Related Instruments
    BDX
    BDX
    -2.040
    (-0.90%)
    225.190 USD
    B
    BIO
    -30.13
    (-8.60%)
    320.14 USD
    G
    GH
    -1.065
    (-3.53%)
    29.130 USD
    H
    HOLX
    1.040
    (1.34%)
    78.600 USD
    ISRG
    ISRG
    -10.30
    (-1.92%)
    547.83 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    P
    PKI
    1.920
    (1.57%)
    124.190 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    513.04 USD
    T
    TRIB
    -0.07000
    (-4.76%)
    1.40000 USD
    V
    VCYT
    -1.085
    (-2.93%)
    35.955 USD
    More
News

Title: Cytosorbents Corp

Sector: Healthcare
Industry: Medical Devices
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.